The efficacy and safety of a novel PD‐1/CTLA‐4 bispecific antibody cadonilimab (AK104) in advanced non‐small cell lung cancer: A multicenter retrospective observational study.

Autor: Li, Hongxin1 (AUTHOR), Zhao, Wen2 (AUTHOR), Li, Chengming3 (AUTHOR), Shen, Hongchang4 (AUTHOR), Li, Meiying5 (AUTHOR), Wang, Chengjun2 (AUTHOR), Han, Chunyan6,7 (AUTHOR), Yi, Cuihua2 (AUTHOR), Wang, Jun8,9 (AUTHOR), Meng, Xue3 (AUTHOR), Liu, Lian2 (AUTHOR), Yu, Shuwen10,11 (AUTHOR), Li, Jisheng2 (AUTHOR) lijisheng@sdu.edu.cn
Zdroj: Thoracic Cancer. Nov2024, Vol. 15 Issue 32, p2327-2338. 12p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje